Cho Yena, Kim Yong Kee
Research Institute of Pharmaceutical Sciences, College of Pharmacy, Sookmyung Women's University, Seoul, South Korea.
Front Oncol. 2020 Jun 2;10:764. doi: 10.3389/fonc.2020.00764. eCollection 2020.
Multidrug resistance (MDR), which is a significant impediment to the success of cancer chemotherapy, is attributable to various defensive mechanisms in cancer. Initially, overexpression of ATP-binding cassette (ABC) transporters such as P-glycoprotein (P-gp) was considered the most important mechanism for drug resistance; hence, many investigators for a long time focused on the development of specific ABC transporter inhibitors. However, to date their efforts have failed to develop a clinically applicable drug, leaving only a number of problems. The concept of cancer stem cells (CSCs) has provided new directions for both cancer and MDR research. MDR is known to be one of the most important features of CSCs and thus plays a crucial role in cancer recurrence and exacerbation. Therefore, in recent years, research targeting CSCs has been increasing rapidly in search of an effective cancer treatment. Here, we review the drugs that have been studied and developed to overcome MDR and CSCs, and discuss the limitations and future perspectives.
多药耐药性(MDR)是癌症化疗成功的重大障碍,它归因于癌症中的各种防御机制。最初,诸如P-糖蛋白(P-gp)等ATP结合盒(ABC)转运蛋白的过表达被认为是耐药性的最重要机制;因此,长期以来许多研究人员专注于开发特异性ABC转运蛋白抑制剂。然而,迄今为止,他们的努力未能开发出临床适用的药物,只留下了一些问题。癌症干细胞(CSC)的概念为癌症和MDR研究提供了新方向。已知MDR是CSC的最重要特征之一,因此在癌症复发和恶化中起关键作用。因此,近年来,针对CSC的研究迅速增加,以寻找有效的癌症治疗方法。在此,我们综述了为克服MDR和CSC而研究和开发的药物,并讨论了其局限性和未来前景。